Celltrion has been granted a patent for a stable liquid pharmaceutical formulation containing infliximab, surfactant, sorbitol, and sodium acetate. The formulation has low viscosity, high antibody content, and excellent long-term storage stability, suitable for subcutaneous administration. GlobalData’s report on Celltrion gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Celltrion Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Celltrion, Peptide nano-particle conjugates was a key innovation area identified from patents. Celltrion's grant share as of April 2024 was 28%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11951207B2) discloses a stable liquid pharmaceutical formulation of infliximab, an important medication used to treat various inflammatory conditions. The formulation includes specific concentrations of infliximab, a surfactant (polysorbate 80), a sugar (sorbitol), and a buffer (sodium acetate). Notably, the formulation is free of certain amino acids and salts, ensuring its stability and efficacy.

Furthermore, the patent claims specify additional features of the formulation, such as a defined pH range, viscosity levels after storage under specific conditions, and optional inclusion of Taurine. The formulation can be conveniently administered using a pre-filled syringe or an auto-injector, making it suitable for patients requiring regular dosing. Additionally, a kit containing the formulation and administration instructions is also part of the patent claims, emphasizing the importance of proper guidance for patients using the medication. Overall, the patent highlights the unique composition and stability of the liquid pharmaceutical formulation of infliximab, offering potential benefits for individuals managing inflammatory conditions.

To know more about GlobalData’s detailed insights on Celltrion, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies